Kinnate Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Kinnate Biopharma

16/05/2022 22:01

* Kinnate Biopharma Inc  KNTE.OQ  reported a quarterly
adjusted
loss of 61 cents​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 61 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Kinnate Biopharma Inc's reported EPS for the quarter was a
loss
of 61 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Kinnate Biopharma Inc shares had fallen by 17.9% this
quarter and lost 47.8% so far this year.
    * The company reported a quarterly loss of $26.9 million.
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $39.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 09:00 p.m.  ​All
figures in US dollars unless otherwise stated